Ripretinib, a novel Type II TKI specifically designed to target a broad spectrum of KIT and PDGFRA mutations by switching the kinase back to its inactive state, approved in 2020, is recommended for GIST patients who have received at least three prior kinase inhibitors, positioning it as a fourth‐line treatment option [17]. Here, KIT is linked to gastrointestinal stromal tumor.